Most Read Articles
2 days ago
Rivaroxaban leads to less major bleeding than warfarin when used to treat nonvalvular atrial fibrillation in patients with stage 4 or 5 chronic kidney disease, a recent study has found.
Jairia Dela Cruz, 4 days ago
Toileting behaviours such as convenience and delayed voiding, straining to void, and position preference are strongly associated with overactive bladder (OAB) symptoms in women, according to a study.
3 days ago
The risk of cancer is higher among patients with atrial fibrillation (AF), a recent study has found. Among important risk factors are comorbidities such as diabetes, hypertension and liver cirrhosis.
Pearl Toh, 2 days ago
As-needed budesonide–formoterol (ICS* + LABA**) reliever therapy was more effective than maintenance low-dose budesonide plus as-needed terbutaline (maintenance ICS + as-needed SABA***) for preventing severe exacerbations in patients with mild asthma, according to the PRACTICAL study presented at ERS 2019.

Product Highlight - Lonsurf

29 Mar 2019
  • Active Ingredient: Trifluridine, tipiracil (as hydrochloride)
  • Indications: Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
  • Dosage & Administration: The recommended starting dose of Lonsurf in adults is 35 mg/m2/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long as benefit is observed or until unacceptable toxicity occurs.
    Lonsurf is for oral use. The tablets must be taken with a glass of water within 1 hour after completion of the morning and evening meals.
  • Presentation: 15 mg/6.14 mg FC tab 2 x 10’s. 20 mg/8.19 mg FC tab 2 x 10’s.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Rivaroxaban leads to less major bleeding than warfarin when used to treat nonvalvular atrial fibrillation in patients with stage 4 or 5 chronic kidney disease, a recent study has found.
Jairia Dela Cruz, 4 days ago
Toileting behaviours such as convenience and delayed voiding, straining to void, and position preference are strongly associated with overactive bladder (OAB) symptoms in women, according to a study.
3 days ago
The risk of cancer is higher among patients with atrial fibrillation (AF), a recent study has found. Among important risk factors are comorbidities such as diabetes, hypertension and liver cirrhosis.
Pearl Toh, 2 days ago
As-needed budesonide–formoterol (ICS* + LABA**) reliever therapy was more effective than maintenance low-dose budesonide plus as-needed terbutaline (maintenance ICS + as-needed SABA***) for preventing severe exacerbations in patients with mild asthma, according to the PRACTICAL study presented at ERS 2019.